Interactive graphics in Pharma R&D: The right decision
description
Transcript of Interactive graphics in Pharma R&D: The right decision
![Page 1: Interactive graphics in Pharma R&D: The right decision](https://reader035.fdocuments.us/reader035/viewer/2022070410/56814596550346895db28751/html5/thumbnails/1.jpg)
Interactive graphics in Pharma R&D:The right decision
mg r af ti
Francois Mercier, @mgrafitStrata-EU 2013, London, 12-Nov-2013
![Page 2: Interactive graphics in Pharma R&D: The right decision](https://reader035.fdocuments.us/reader035/viewer/2022070410/56814596550346895db28751/html5/thumbnails/2.jpg)
MultipleSclerosis
1/12
2,500,000 People with MS, in the worldMainly in western countriesMainly women 35-45 y.o.
#15 in R&D spending (~2 $bn/yr)
*http://www.imshealth.com/, http://www.nationalmssociety.org/index.aspx
Price of a marketed MS treatment
30-45 k€/year/patient
Cost &Pr(Failure)
Development of a new drug in MS
300-600 M€
7-12 years
![Page 3: Interactive graphics in Pharma R&D: The right decision](https://reader035.fdocuments.us/reader035/viewer/2022070410/56814596550346895db28751/html5/thumbnails/3.jpg)
ComplexSystems
2/12
![Page 4: Interactive graphics in Pharma R&D: The right decision](https://reader035.fdocuments.us/reader035/viewer/2022070410/56814596550346895db28751/html5/thumbnails/4.jpg)
PharmaR&D
Roadmap
3/15
Target identificati
on
Lead discover
y
Lead optimizatio
n
Pre-clinical ADME
Phase I (FiH, safety
profiling)IND
Phase II
PoCEOP2
Phase III (confirmat
ory)
NDAReview MA
![Page 5: Interactive graphics in Pharma R&D: The right decision](https://reader035.fdocuments.us/reader035/viewer/2022070410/56814596550346895db28751/html5/thumbnails/5.jpg)
RegulatoryEnviro-nment
4/15
IN THE INTEREST OFALL,
STAY INSIDE THE BOX
Data analyses have to be reproducible• Source data are safely stored and data manipulation are traced• Data analyses are available in the form of programs (no GUI)
![Page 6: Interactive graphics in Pharma R&D: The right decision](https://reader035.fdocuments.us/reader035/viewer/2022070410/56814596550346895db28751/html5/thumbnails/6.jpg)
From PatientTo Data
5/15
Subject (healthy or ill)
Physician
Nurse
Data Warehous
e
Mobile devices (cardiac
function, vital signs)
Labs (biofluids, images, other
samples)
100 subjects ≈ 1-5 GB
![Page 7: Interactive graphics in Pharma R&D: The right decision](https://reader035.fdocuments.us/reader035/viewer/2022070410/56814596550346895db28751/html5/thumbnails/7.jpg)
From Data ToDecision
6/15
Data manager
Data scientist
Clinical project leader
Therapeutic area head
Clinical development head
Pharmaceutical division head
Raw data
Distillated information
![Page 8: Interactive graphics in Pharma R&D: The right decision](https://reader035.fdocuments.us/reader035/viewer/2022070410/56814596550346895db28751/html5/thumbnails/8.jpg)
ClinicalDevelop.Strategy
7/15
In clinical projects, a strategy is defined as a compromise between money
and science
€
3√𝑅𝑥
Data manager
Data scientist
Clinical project leader
Therapeutic area head
Clinical development head
Pharmaceutical division head
![Page 9: Interactive graphics in Pharma R&D: The right decision](https://reader035.fdocuments.us/reader035/viewer/2022070410/56814596550346895db28751/html5/thumbnails/9.jpg)
DecisionMakingProcess
8/15
Communicate
Collect
?
Visualize
Model
Refine
![Page 10: Interactive graphics in Pharma R&D: The right decision](https://reader035.fdocuments.us/reader035/viewer/2022070410/56814596550346895db28751/html5/thumbnails/10.jpg)
Commu-Nication
Risks
9/15
Loss of informationMute assumptions
CompromisesLack of integration
Misinterpretation
RISKS
How to mitigate these risks?
Raw data
Distillated information
We use models and graphics
![Page 11: Interactive graphics in Pharma R&D: The right decision](https://reader035.fdocuments.us/reader035/viewer/2022070410/56814596550346895db28751/html5/thumbnails/11.jpg)
Models&
Graphics
10/15
Model Visualize
Two sides of the same coin
− Mathematical language+ Assumptions
+ Universal language− Limited in space and form (2D)
*Data from Nakov et al. Am. J. Hypertension, 2002, 15:583-9.
10 30 100
Darusentan dose (mg)*
DSB
P (m
m H
g)
• Gaussian distrib⁰• Homoscedasticity• Dose is discrete
![Page 12: Interactive graphics in Pharma R&D: The right decision](https://reader035.fdocuments.us/reader035/viewer/2022070410/56814596550346895db28751/html5/thumbnails/12.jpg)
Real lifeIs
Complex
11/15
How many static graphics to depict this model?
![Page 15: Interactive graphics in Pharma R&D: The right decision](https://reader035.fdocuments.us/reader035/viewer/2022070410/56814596550346895db28751/html5/thumbnails/15.jpg)
Conclusion
14/15
• Give control to the end-user• Make scientific discussions an enjoyable experience• Provide context, perspective• Make the assumptions explicit
Interactive graphics in Pharma R&D:The right decision
To take quick and accurate decisions
![Page 16: Interactive graphics in Pharma R&D: The right decision](https://reader035.fdocuments.us/reader035/viewer/2022070410/56814596550346895db28751/html5/thumbnails/16.jpg)
AcknowLedgments
15/15
Jean Mercier (http://www.khawai.com/)
Olivier Luttringer (Novartis)
Hadley Wickham (http://had.co.nz/)
Mike Bostock (http://bost.ocks.org/mike/)